Non-steroidal anti-inflammatory drugs (
NSAIDs) and other
eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory,
antipyretic, and
analgesic effects are applied against symptoms of
respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with
allergy and
asthma. However, the current pandemic of
COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during
viral infections and
inflammation, but also in
asthma exacerbations, uncontrolled allergic
inflammation, and
NSAIDs-exacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of
NSAIDs in
COVID-19, and the role of
NSAIDs in
asthma and viral
asthma exacerbations. We also describe here novel mechanisms of action of
leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA
therapy and discuss a potential role of LTRA
therapy in
COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other
eicosanoid pathway modifiers on the horizon, such as
prostaglandin D2 antagonists and
cannabinoids, with
eicosanoid pathways, in context of
viral infections and exacerbations of
asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current
eicosanoid research.